[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603095":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":27,"locations":19,"responsibleParty":34,"collaborators":19,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":19,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":19,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":58,"whyStopped":19,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":19},{"fullName":5,"class":6},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ultrahypofractionation Phase","EXPERIMENTAL","MR-Guided Ultrahypofractionation",[13],"Radiation: MR-guided Irradiation",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","MR-guided Irradiation",[9],null,[21,25],{"name":22,"affiliation":23,"role":24},"Rafael Martínez-Monge, M.D.","Clínica Universidad de Navarra","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":23,"role":24},"Luis Fuertes, M.D.",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Beatriz Ramos Aguirre, M.S.","CONTACT","+34 948255400","2772","ucicec@unav.es",{"type":35,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100603095","mri-guided-dose-intensification-program-locally-advanced-pancreatic-cancer-100603095",false,"NCT07132060","MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Selection criteria includes patients with unresectable and borderline resectable and medically inoperable pancreatic cancer that will receive neoadjuvant chemotherapy followed by chemoirradiation.\n* No prior radiation therapy to the target areas;\n* Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including neoadjuvant chemotherapy followed by chemoirradiation.\n* WBC equal or greater than 3500 mm\\^3; platelet count equal or greater than 135000 mm\\^3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n\nExclusion Criteria:\n\n* Inability to undergo an MRI scan","ALL","18 Years","80 Years",{"count":46,"type":47},30,"ESTIMATED","INTERVENTIONAL",[50],"NA","The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer",[53],"Pancreatic Cancer",[55,56,57],"MRI-guided irradiation","Dose escalation","Ultrahypofractionation","NOT_YET_RECRUITING","2025-08-20",{"date":61,"type":62},"2025-08-27","ACTUAL",{"date":64,"type":47},"2025-10-01",{"date":66,"type":47},"2030-06-30",{"name":5,"class":6}]